EUCTR2004-000730-37-CZActive, not recruitingPhase 1
A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose-response phase III A study to evaluate safety and efficacy of Prolonged Release (PR) OROS methylphenidate (18, 36 and 72 mg/day), with open-label extension, in adults with attention deficit/ hyperactivity disorder. - LAMDA
Janssen-Cilag Medical Affairs EMEA0 sites0 target enrollmentStarted: March 1, 2005Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1.Subjects can be male or female.2.Age must be aged between 18 and 65 years, inclusive.3.Diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental Diseases, Fourth Edition (DSM-IV)1,50 and confirmed by the Conners' Adult ADHD Diagnostic Interview for DSM IV.4.Described chronic course of ADHD symptomatology from childhood to adulthood, with some symptoms present before age 7 years and continue to meet DSM-IV criteria at the time of assessment. ADHD is not diagnosed if the symptoms are better accounted for by another psychiatric disorder (e.g. mood disorder (especially bipolar disorder), anxiety disorder, psychotic disorder, personality disorder).5.CAARS score of >= 24 as determined by investigator at screening visit.6.Female subjects of child-bearing potential must agree to use an acceptable form of contraception (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilisation) before entry and throughout the study, and must have a negative urine pregnancy test at screening.7.Informed Consent Form signed by the subject.8.Subject agrees to take only the supplied study drug as treatment for ADHD during the study.9.Subject agrees not to initiate a new behavioural modification programme during the study or if currently using a behavioural modification programme and agrees not to change this programme during the study.10.Subject is able to comply with the study visit schedule and willing and able to complete the protocol-specified assessments.11.Healthy on the basis of a physical examination, medical history, anamnesis, and the results of blood biochemistry or haematology tests. If the results of the biochemistry or haematology tests are not within the laboratory's normal reference ranges, the subject may be included if the investigator considers the deviations are not clinically relevant. This should be clearly recorded in the subject's source documents and the Trial Manager informed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1.Known to be a non-responder to methylphenidate, or subject has a child known to be a non-responder to methylphenidate.2.Has been treated with any methylphenidate-containing medication within 1 months of screening visit. One months is considered a reasonable time for patients treated with methylphenidate to return to a disease status baseline.3.Known allergy or hypersensitivity to methylphenidate, or components of PR OROS methylphenidate.4.Any clinically unstable psychiatric condition including but not limited to the following: acute mood disorder, bipolar disorder, acute obsessive-compulsive disorder (OCD), anti-social personality disorder, Borderline Personality Disorder.5.Subjects with a family history of schizophrenia or family history of affective psychosis.6.Autism or Asperger's syndrome.7.Subjects with presence of motor tics, history of Tourette's syndrome or family history of Tourette's syndrome.8.A diagnosis of substance use disorder (abuse/dependence) according to DSM-IV criteria within 6 months prior to screening evaluation (nicotine and caffeine dependence are not exclusionary). Episodic abuse in the past is not an exclusion criterion.9.Current eating disorder (e.g. bulimia, anorexia nervosa) or history of an eating disorder.10.Known or suspected mental retardation.11.Hyperthyroidism, myocardial infarction or stroke in the 6 months prior to screening for this study.12.Subjects with history of seizures, glaucoma or uncontrolled hypertension.13.Subjects with angina pectoris or cardiac arrhythmias.14.Pregnant or breast-feeding females.15.Any co-existing medical condition or taking any concomitant medication that is likely to interfere with safe administration of methylphenidate including any herbal or homeopathic remedies; herbal and over-the-counter weight loss or diet preparations or drugs that contain stimulants.16.Use of monoamine oxidase inhibitors, except if tapering off, within 4 weeks of the baseline visit.17.Use of other anti-depressants (unless subject has been on a stable dosage for at least 3 months prior to screening, in which case treatment may continue so long as dosage remains unchanged for the duration of the study) or mood stabilisers (e.g. anti-epileptics, lithium), except if tapering off, within 2 weeks of the baseline visit (for fluoxetine within 4 weeks). Any medication likely to interfere with safe administration of methylphenidate.18.Use of clonidine or other alpha-2 adrenergic receptor agonists, antipsychotic medications, theophylline, coumarin anticoagulants, anticonvulsants.19.Subjects who have clinically significant gastrointestinal problems, including severe narrowing (pathologic or iatrogenic) of the gastrointestinal tract.20.Subjects who are unable to swallow the study medication whole with the aid of liquids (participants may not chew, divide, dissolve or crush the study medication).21.History of severe drug allergy or hypersensitivity.22.Any serious illnesses including, but not limited to liver or renal insuffiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, psychiatric or metabolic disturbances. 23. Confirmed cancer or malignancy. 24. Participation in an investigational drug trial in the 30 days prior to selection. 25. Employee of the investigator or the institution who have direct involvement in the trial or other trials under the direction of the investigator or their members.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A multicentre, randomised, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure syndrome and renal impairment who are hospitalised for volume overload and require intravenous diuretic therapy. - PROTECT {CKI-302}Patients being admitted to hospital for acute heart failure (AHFS) with volume overload and renal impairment.MedDRA version: 9.1Level: LLTClassification code 10000803Term: Acute heart failureEUCTR2006-001637-18-SEovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc)1,000
Active, not recruiting
Not Applicable
A research study of a new drug (MT-102) for patients with weight loss and weakness (cachexia) related to lung or colorectal cancerCachexia related to stage III and IV non-small cell lung cancer and colorectal cancerMedDRA version: 14.1Level: LLTClassification code 10064015Term: Cancer cachexiaSystem Organ Class: 100000004861EUCTR2010-022486-10-DEPsioxus Therapeutics Limited129
Active, not recruiting
Not Applicable
A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjunction with a single intravenous dose of ondansetron for the prevention of post-operative and post-discharge nausea and vomiting in at risk females undergoing laparoscopic/laparotomic surgical procedures.EUCTR2004-000369-37-DKGlaxoSmithKline Group of Companies411
Active, not recruiting
Phase 1
A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma.EUCTR2009-014415-12-GBGlaxoSmithKline Research & Development Ltd
Active, not recruiting
Not Applicable
A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma.severe uncontrolled refractory asthma.MedDRA version: 12.0Level: LLTClassification code 10003553Term: AsthmaEUCTR2009-014415-12-PLGlaxoSmithKline Research & Development Ltd604